Registry of Asthma Patients Initiating DUPIXENT

  • STATUS
    Recruiting
  • End date
    Sep 16, 2025
  • participants needed
    1000
  • sponsor
    Regeneron Pharmaceuticals
Updated on 13 August 2021
Investigator
Clinical Trials Administrator
Primary Contact
Regeneron Study Site (3.8 mi away) Contact
+65 other location

Summary

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT in a real-world setting to understand the attributes of treated patients in real life.

This includes characterization of:

  • Patient demographics (eg, gender, age, and race)
  • Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height)

The secondary objectives of the study are:

  • To characterize real-world use patterns of DUPIXENT for asthma
  • To assess the long-term effectiveness of DUPIXENT in asthma patients in a real-world setting
  • To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT
  • To collect long-term safety data on study participants in the real-world setting

Description

3-year registry of real-world use of DUPIXENT for asthma in patients age 12 and over

Details
Condition Asthma, Allergies & Asthma, Asthma (Pediatric), asthmatic, bronchial asthma
Treatment DUPIXENT®
Clinical Study IdentifierNCT04287621
SponsorRegeneron Pharmaceuticals
Last Modified on13 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Willing and able to comply with the required clinic visits, study procedures and assessments
Able to understand and complete study-related questionnaires
Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required
Initiating treatment with DUPIXENT for a primary indication of asthma according to the country-specific prescribing information

Exclusion Criteria

Patients who have a contraindication to DUPIXENT according to the country-specific prescribing information
Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments
NOTE: Other protocol defined Inclusion/Exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note